Femasys (NASDAQ:FEMY) PT Raised to $12.00

Femasys (NASDAQ:FEMYGet Free Report) had its price target raised by analysts at HC Wainwright from $10.00 to $12.00 in a report issued on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright also issued estimates for Femasys’ Q1 2024 earnings at ($0.22) EPS, Q2 2024 earnings at ($0.24) EPS, Q3 2024 earnings at ($0.21) EPS, Q4 2024 earnings at ($0.22) EPS and FY2028 earnings at ($0.14) EPS.

Several other equities research analysts have also commented on FEMY. Chardan Capital reaffirmed a “buy” rating and set a $12.00 price target on shares of Femasys in a research report on Thursday, March 21st. Jonestrading upped their price target on shares of Femasys from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Wednesday, March 20th.

Get Our Latest Stock Analysis on FEMY

Femasys Price Performance

Shares of NASDAQ:FEMY opened at $1.74 on Monday. Femasys has a fifty-two week low of $0.25 and a fifty-two week high of $4.75. The business has a 50-day simple moving average of $1.45 and a two-hundred day simple moving average of $1.24. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.40 and a current ratio of 4.68. The firm has a market cap of $37.67 million, a price-to-earnings ratio of -1.89 and a beta of -3.00.

Femasys (NASDAQ:FEMYGet Free Report) last issued its earnings results on Thursday, March 28th. The company reported ($0.19) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.19). Femasys had a negative return on equity of 119.80% and a negative net margin of 1,329.10%. The business had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.30 million. On average, analysts expect that Femasys will post -0.74 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Cetera Advisor Networks LLC bought a new position in shares of Femasys during the 1st quarter valued at approximately $27,000. Vanguard Personalized Indexing Management LLC bought a new position in Femasys in the 3rd quarter worth approximately $35,000. Virtu Financial LLC bought a new position in Femasys in the 2nd quarter worth approximately $39,000. LPL Financial LLC bought a new position in Femasys in the 2nd quarter worth approximately $51,000. Finally, Cambridge Investment Research Advisors Inc. bought a new position in Femasys in the 1st quarter worth approximately $68,000. 65.27% of the stock is currently owned by institutional investors.

About Femasys

(Get Free Report)

Femasys Inc, a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.

Recommended Stories

Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.